What is MiRXES?
Founded in 2014, MiRXES operates at the intersection of advanced microRNA research and clinical application. By leveraging a proprietary technology platform, the company specializes in the discovery and incubation of diagnostic tools that address critical needs in the medical, pharmaceutical, and agricultural sectors. MiRXES distinguishes itself through its world-class R&D and manufacturing capabilities, which facilitate the development of accurate, accessible, and affordable diagnostic solutions. The company's ecosystem-based approach, which integrates clinicians, researchers, and corporate partners, is designed to accelerate the transition of innovative science from the laboratory to the bedside, ultimately aiming to improve patient outcomes and eradicate disease.
How much funding has MiRXES raised?
MiRXES has raised a total of $167M across 3 funding rounds:
Series C
$77M
Series D
$50M
Debt
$40M
Series C (2021): $77M with participation from Rock Springs Capital, EDBI, and CR-CP Life Science Fund
Series D (2023): $50M led by Fupu Investment Management, NHH Venture Fund, and Mitsui & Co.
Debt (2025): $40M supported by CBC Group
Key Investors in MiRXES
CBC Group
CBC Group is a prominent healthcare-focused investment firm in Asia that specializes in platform-building and buyout opportunities across the pharmaceutical, biotech, and medtech sectors.
Mitsui & Co.
Mitsui & Co. is a diversified global trading and investment conglomerate that leverages its extensive geographic reach to support healthcare innovation and sustainable industry growth.
Rock Springs Capital
Rock Springs Capital is a specialized investment firm focused on identifying and supporting high-growth companies within the healthcare and biotechnology industries.
What's next for MiRXES?
With this latest capital injection, MiRXES is well-positioned to accelerate its international expansion and deepen its R&D pipeline. The strategic focus will likely center on enhancing its microRNA biomarker profiling efforts to address unmet medical needs in oncology and chronic disease management. By utilizing the recent financing to bolster its operational infrastructure and strengthen its global network, MiRXES is poised to solidify its market leadership. The company's ability to maintain a strong, collaborative ecosystem will be pivotal as it navigates the complexities of the global biotech landscape, aiming to deliver high-impact, data-driven healthcare solutions that meet the evolving demands of the medical community.
See full MiRXES company page
